  ESBATech AG (Zurich, Switzerland) has achieved high concentrations of its antibody  fragments in all segments of the eye with topical delivery via eye drops. These  data were confirmed in several independent preclinical 

  Anticipated therapeutic concentrations of ESBATech’s  antibody fragments were observed in the anterior chamber (front of the eye) and  in the posterior segments (back of the eye) including the vitreous humor, retina,  and choroid. ESBATech’s lead antibody fragment, ESBA105, is a TNF-alpha antagonist  that is scheduled to enter clinical development later in 2008. 

  Antibody fragments are an emerging area of focus  within the monoclonal antibody market and represent a new class of  therapeutics. Because of their smaller molecular size, antibody fragments have  a number of advantages over whole antibodies. Antibody fragments comprise only  the naturally occurring antigen-binding pocket of the monoclonal antibody, and  not the Fc part that is required to trigger an immune response. This new class  of new products opens applications in indications where no such immune response  is required. Thus, endogenous proteins are preferred targets for these new  biologics.

News

ESBATech AG (Zurich, Switzerland) has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops.